Müller Timo D
a Institute for Diabetes and Obesity, Helmholtz Center Munich, German Research Center for Environmental Health, Technical University Munich, Munich, Germany.
Expert Rev Endocrinol Metab. 2014 Jul;9(4):293-295. doi: 10.1586/17446651.2014.914850. Epub 2014 Apr 28.
Analogs of glucagon-like peptide 1 (GLP-1) are currently one of the best-in class pharmacotherapies to treat obesity and diabetes. Recently advanced biochemical engineering has led to the generation of series of unimolecular co-agonists at receptors for GLP-1 and glucagon or the glucose-dependent insulinotropic polypeptide. In studies from mouse models of obesity and insulin resistance to non-human primates to humans, these tailored molecules have shown to effectively improve several hallmarks of the metabolic syndrome, such as obesity, glucose intolerance and imbalances in cholesterol and lipid metabolism. The aim of this editorial is to briefly summarize the potential of this new class of GLP-1 based therapies for the treatment of the metabolic syndrome.
胰高血糖素样肽1（GLP-1）类似物目前是治疗肥胖症和糖尿病的最佳药物疗法之一。最近先进的生化工程技术已导致生成了一系列针对GLP-1和胰高血糖素受体或葡萄糖依赖性促胰岛素多肽的单分子共激动剂。在从肥胖和胰岛素抵抗小鼠模型到非人类灵长类动物再到人类的研究中，这些量身定制的分子已显示出能有效改善代谢综合征的几个特征，如肥胖、葡萄糖不耐受以及胆固醇和脂质代谢失衡。这篇社论的目的是简要总结这类基于GLP-1的新疗法在治疗代谢综合征方面的潜力。
